Inhaled corticosteroids (ICSs) are a mainstay of COPD treatment for patients with a history of
exacerbations. Initial studies evaluating their use as monotherapy failed to show an effect on …

In this article, we focus on the scientific evidence from randomised trials supporting
treatment with inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease …

The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the treatment of
patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can …

Inhaled corticosteroids (ICS) are now very widely used in high doses in the management of
COPD patients. In sharp contrast to the situation in asthma, ICS provide little or no benefit in …

While the pharmacological management of chronic obstructive pulmonary disease (COPD)
has evolved from the drugs used to treat asthma, the treatment models are different and the …

Current guidelines limit regular use of inhaled corticosteroids (ICS) to a specific subgroup of
patients with chronic obstructive pulmonary disease (COPD) in whom the forced expiratory …

Background The use of inhaled corticosteroids (ICS) in combination with bronchodilators in
patients with COPD has been shown to decrease the rate of disease exacerbations and to …

According to the current clinical practice guidelines for chronic obstructive pulmonary
disease (COPD), the addition of inhaled corticosteroids (ICS) to long-acting β 2 agonist …

Background Conflicting findings exist on the benefit of withdrawal of inhaled corticosteroid
(ICS) in chronic obstructive pulmonary disease (COPD). We performed a quantitative …

The effectiveness of inhaled corticosteroids (ICS) in patients with chronic obstructive
pulmonary disease (COPD) remains controversial. Randomized controlled trials, meta …